← Oncology Approval Tracker

FDA DECISION ·

Penpulimab-kcqx

penpulimab-kcqx · Akeso Biopharma

FDA approvalNew therapyNasopharyngeal carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With gemcitabine and either cisplatin or carboplatin as first-line therapy for adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

LAMPGEN ANALYSIS

Why it matters

The approval introduced penpulimab with platinum-based chemotherapy in first-line recurrent or metastatic non-keratinizing disease.

What research teams should watch

Confirm histology and allow documentation of the platinum choice and supportive care needs across treatment sites.

PRIMARY RECORDS

Sources